Trials / Completed
CompletedNCT00596791
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Santen Oy · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tafluprost | prostaglandine analoque |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-07-01
- Completion
- 2008-08-01
- First posted
- 2008-01-17
- Last updated
- 2009-01-12
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00596791. Inclusion in this directory is not an endorsement.